 A Message From Awesomely Thanks to a new law Trump just signed… Every day until April 2027 the entire GDP of Switzerland will migrate onto Trump's New Money Grid, that's $909 billion. Every single day. That's every bank account, every fund, every mortgage, every stock trade in America. Translation: our entire financial system is migrating onto a new blockchain-based Money Grid. And every dollar that moves burns one scarce asset. That's why BlackRock, JPMorgan, Goldman Sachs and Fidelity are hoarding shares like it's Black Friday. Get in on the trade BlackRock, JPMorgan, and Fidelity are already making. The Nasdaq just got SEC approval to move stocks onto blockchain rails. BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to it. The World Economic Forum says 2026 is "a defining moment" for this new financial infrastructure. Everyone who's actually building this thing is saying the same thing… This is not a drill. This is the biggest overhaul of America's money system since we stopped using gold coins. And at the center of it all? A scarce asset that gets burned every single time a transaction happens. Block Chain expert Andy Howard is calling it "Digital Oil." And right now, before this goes mainstream, you can still get in at prices the institutions would love to lock in forever. Get the name. The ticker. And exactly how to buy here. Your future looks bright, Andy Howard
The Edge™ Senior Blockchain Analyst PS I'm predicting this could potentially be one of, if not THEE most explosive wealth opportunities I've come across. That's why you can't drag your feet here, because once retail investors catch wind of this, it will be too late… Click here before it's too late to get in on the trade.
Just For You
Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis BidAuthor: Jeffrey Neal Johnson. Publication Date: 9/15/2026. 
Key Points
- Curaleaf took a hostile tender offer directly to Aurora Cannabis shareholders, valuing the target at about $4 per share, a 45% premium.
- The deal would pair Curaleaf's $1.27 billion domestic revenue base with Aurora Cannabis's low-leverage balance sheet and international medical export network in Europe.
- Expected removal of Section 280E tax burdens and rising MSOS options activity suggest investors anticipate broader cannabis sector consolidation and valuation re-rating.
- Special Report: Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
Cross-border consolidation in the cannabis industry has moved from executive speculation to aggressive dealmaking. As regulatory hurdles begin to clear across North America and Europe, operators are moving quickly to strengthen their finances and expand internationally. Curaleaf Holdings, Inc. (OTCMKTS: CURLF) bypassed Aurora Cannabis management and took an acquisition proposal directly to Aurora Cannabis Inc. (NASDAQ: ACB) shareholders. By offering a cash-and-stock package valued at approximately $4 per share, Curaleaf is attempting to build an international commercial footprint spanning 17 countries.
For investors tracking capital flows and federal policy changes, this hostile bid signals that the era of fragmented regional cannabis operators may be coming to a close. The proposed deal also shows how industry leaders are using their financial strengths to gain scale ahead of expected federal reforms. Curaleaf Takes Its Case to ShareholdersThe deal moved forward when Curaleaf went public with its formal tender offer, appealing directly to shareholders after private merger discussions stalled. The proposal offers 0.3463 Curaleaf common shares and 75 cents in cash for each Aurora Cannabis share tendered. Based on Aurora Cannabis's unaffected 30-day volume-weighted average price (VWAP) of $2.76 on Aug. 10, 2026, the bid implies a purchase price of $4 per share, representing a 45% acquisition premium. Shareholder tensions escalated on Sept. 14, 2026, when Curaleaf filed an application with the Alberta Securities Commission seeking an order to cease trading or halt Aurora Cannabis's active at-the-market (ATM) equity distribution facility. Curaleaf contends that Aurora Cannabis leadership is using continuous share issuances as a defensive maneuver to dilute shareholder voting power and entrench management. In recent years, Aurora Cannabis has raised more than $400 million through equity offerings, selling shares for as little as $2.60 in July 2026. Curaleaf Chairman Boris Jordan scheduled an open shareholder webcast for Sept. 17, 2026, to present the strategic case directly to investors ahead of the Dec. 1, 2026, tender expiration. Merging High Sales With Low LeverageBeneath the boardroom fight lies a compelling balance-sheet transaction. Curaleaf operates at substantial scale in the domestic market, recording annual net revenue of approximately $1.27 billion. In its latest quarterly report, the company delivered $340.1 million in revenue and 5 cents in adjusted earnings per share, outperforming consensus estimates. Continued expansion in state-level retail has left Curaleaf with a debt-to-equity ratio of 1.06 and operating cash flow of 17 cents per share. By contrast, Aurora Cannabis offers a cash-rich, low-leverage balance sheet. The company has a minimal debt-to-equity ratio of 0.03 and a current ratio of 5.36, along with a book value of $6.27 per share. Despite these balance-sheet strengths, Aurora Cannabis faces operational headwinds, including annual revenue of approximately $247.82 million, a negative net profit margin of 32.26%, and several quarters of top-line contraction. Acquiring Aurora Cannabis would allow Curaleaf to access its liquidity at approximately 0.60 times book value. Pro forma estimates indicate that the combined organization would generate more than $1.5 billion in annual revenue and approximately $350 million in adjusted EBITDA. Eliminating duplicative public-listing expenses, centralizing supply-chain logistics, and streamlining corporate overhead are expected to produce at least $40 million in annualized cost efficiencies and operating savings. German Exports Meet American ReformThe timing of this takeover bid aligns with regulatory tailwinds in both North America and Europe. In the U.S., administrative momentum surrounding the reclassification of cannabis under Schedule III of the Controlled Substances Act could eliminate the impact of Internal Revenue Code Section 280E. This federal tax provision prevents cannabis operators from deducting ordinary business expenses, frequently pushing effective corporate tax burdens above 70%. Removing Section 280E would immediately expand Curaleaf's cash flow, easing the capital required to fund the 75-cent cash component of the tender offer. At the same time, Aurora Cannabis provides a turnkey medical export platform that U.S. operators cannot build domestically under existing federal restrictions. The company holds established distribution agreements across mature medical markets, including Germany, the United Kingdom, Poland, and Australia. Following recent German medical cannabis reforms that simplified patient prescription procedures, demand for standardized, pharmaceutical-grade imports has expanded significantly. Combining Curaleaf's domestic retail presence with Aurora Cannabis's international commercial network would provide immediate access to European health care channels. The Green Spread: Why MSOS Call Volume Points to a Re-RatingPublic market pricing reflects growing confidence in cross-border consolidation. With Aurora Cannabis shares trading near $3.80, the stock sits at a narrow 5% discount to the implied $4 acquisition price. This tight arbitrage spread suggests that the market anticipates either a successful deal or a sweetened bid from the acquirer. Institutional sentiment is also visible across sector exchange-traded funds. The AdvisorShares Pure US Cannabis ETF (NYSEARCA: MSOS) saw a sharp surge in derivatives positioning, recording daily volume of 52,583 contracts. Options flows showed extreme call-side skew, with 46,416 call options trading against only 6,167 put options, producing an 88.3% call ratio. Because Curaleaf accounts for approximately 21.6% of the fund's underlying exposure through direct stock and swap contracts, institutional desks appear to be using the ETF to position for a broader valuation re-rating. Elevated short interest of roughly 9.79 million shares adds fuel to a potential short-covering advance if consolidation gains momentum. Pruning the Risk and Weighing the UpsideInvestors monitoring the cannabis sector should view this hostile bid as a potential catalyst for widespread industry realignment. Aurora Cannabis shareholders must weigh the potential liquidity provided by a 45% premium against management's standalone turnaround timeline before the Dec. 1, 2026, deadline. Immediate investor focal points include the Sept. 17 executive Q&A, the pending Alberta Securities Commission ruling on the ATM facility, and upcoming quarterly corporate filings. While integration challenges and potential regulatory delays in cross-border approvals remain risks, the commercial logic of combining scale, international reach, and balance-sheet liquidity is difficult to dismiss. Investors seeking exposure to sector-wide consolidation might consider Curaleaf for its established market presence or monitor Aurora Cannabis to evaluate event-driven arbitrage spreads. Those seeking broader exposure without the regulatory risk associated with a single operator may consider diversified funds such as the AdvisorShares Pure US Cannabis ETF on minor price pullbacks as federal policy shifts unfold.
If you no longer wish to receive these emails, unsubscribe here.
. |
